Cariprazine

General information

Indicated for: VRAYLAR is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults ( 1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults ( 1 ) Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1 ) Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 )

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 1.5–6 mg/day

Mechanism (brief)

D3/D2 partial agonist (D3‑preferring); 5‑HT1A partial agonist; 5‑HT2A antagonist.

Metabolism & Half‑life

• Metabolism: CYP3A4, active metabolites with long half‑lives.
• Half‑life: Long effective half‑life due to metabolites (days).

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually

Sources

• Cariprazine label — DailyMed (2025)